ArticleBMJ public health2025

Estimating the economically justifiable price of nirsevimab versus standard of practice for the prevention of respiratory syncytial virus infections in neonates and infants in Spain: a cost-utility modelling study.

Ruth Gil-Prieto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.